Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases.

Chen-Pin WangJohn KuhnDimpy P ShahSusanne SchmidtYui-Wing F LamDaniel MacCarthyLaura TennerAmelie G Ramirez

Published in: Cancer medicine (2019)

Metformin's heterogeneous HCC prevention effect elucidates potential interventions to modify HCC disparity in patients with T2D.

Keyphrases